comparative effectiveness

Research in Review

Second-line Treatment Option Identified for Small Cell Lung Cancer

06/23/2016

JCP Editors

A regimen containing cisplatin, etoposide, and irinotecan may be clinically beneficial as a second-line treatment for certain patients with small cell lung cancer, according to a clinical trial conducted in...

A...

06/23/2016

Journal of Clinical Pathways

Research in Review

Shortened Radiotherapy for Breast Cancer Supported in Study

06/22/2016

JCP Editors

A shortened course of radiotherapy for patients with early stage breast cancer may actually produce slightly better outcomes than the conventional protocol, according to the results of a randomized clinical...

A...

06/22/2016

Journal of Clinical Pathways

Research in Review

Surgery Improves Survival in Patients With Renal Cancer

06/21/2016

JCP Editors

Surgery may improve survival for patients who receive targeted therapies for metastatic renal cell cancer, according to a study by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (Boston,...

...

06/21/2016

Journal of Clinical Pathways

Research in Review

Rectal Cancer Treatment Utilizing Chemotherapy and Radiation Therapy Improving Over Time

06/20/2016

JCP Editors

A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...

...

06/20/2016

Journal of Clinical Pathways

Research in Review

No Difference in Renal Function Decline With ACE inhibitors or ARBs for Diabetes

06/20/2016

JCP Editors

A study comparing the effectivenesses of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for protecting patients with type 2 diabetes from renal function decline found no...

...

06/20/2016

Journal of Clinical Pathways

Research in Review

Outcomes of Treating ALL With Inotuzumab Ozogamicin

06/14/2016

JCP Editors

A clinical trial assessing the use of inotuzumab ozogamicin in patients with acute lymphoblastic leukemia (ALL) has found that it may be a more effective treatment option than current standard practice. Inotuzumab...

A...

06/14/2016

Journal of Clinical Pathways

New Treatment Improves Response in ALK-Positive NSCLC

06/14/2016

JCP Editors

Patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed while on crizotinib (CRZ) may experience improved response rates when treated with the investigational tyrosine kinase...

...

06/14/2016

Journal of Clinical Pathways

Significant Cost Variation in Breast Cancer Chemotherapy

06/13/2016

JCP Editors

A study presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL) has found that the costs associated with different breast cancer chemotherapy regimens can vary...

A...

06/13/2016

Journal of Clinical Pathways

Non-Platinum-Based Chemo May Worsen Survival in Ovarian Cancer

06/10/2016

JCP Editors

Prolonging platinum-free interval (PFI) by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer, according to clinical trial results presented at...

...

06/10/2016

Journal of Clinical Pathways

Discontinuing Treatment With Nivolumab Does Not Affect Survival in Patients With Melanoma

06/10/2016

JCP Editors

Discontinuing nivolumab-ipilimumab treatment because of adverse events may not have a detrimental impact on survival among patients with advanced melanoma, according to follow-up from a randomized trial presented at...

...

06/10/2016

Journal of Clinical Pathways